raised the bar.
If fda request another trial...........puff.......puff....... Ipsen and Active Biotech had been trying to muscle in on an increasingly competitive market. Phase III testing of tasquinimod began four years ago and since then other medicines have reached the market, raising the bar. April 2015 Cancer drug flop sends Ipsen, Active Biotech shares skidding Read more at Reutershttps://www.reuters.com/article/2015/04/16/ipsen-active-biotech-cancer-idUSL5N0XD19G20150416#YvDXmYw6iomgc7xA.99